GlassScriptPhysician profile
Desiree L Long
NPI 1508167644
$1,263.78
in general payments reported to CMS, 2019-2025
25 companies · $680 in 2025
The $680 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $100 · 2022: $44.19 · 2023: $131 · 2024: $308 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,084 · Debt Forgiveness: $35.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,083.78 |
| Debt Forgiveness | $35.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $183.90 | 2021-2025 | |
| Lundbeck LLC | $144.73 | 2023-2025 | Vyepti |
| Sk Life Science, INC. | $135.82 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $107.80 | 2025 | Qelbree |
| Ucb, INC. | $85.55 | 2025 | Briviact, Rystiggo, Fintepla |
| Catalyst Pharmaceuticals, INC. | $77.21 | 2025 | |
| Lilly USA, LLC | $55.98 | 2023-2025 | Emgality, Amyvid |
| Takeda Pharmaceuticals U.S.A., INC. | $52.92 | 2025 | Hyqvia |
| Teva Pharmaceuticals USA, INC. | $45.38 | 2023-2025 | Austedo Xr, Austedo Xr |
| Argenx US, INC. | $44.21 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Baxter Healthcare | $35.61 | 2023-2024 | |
| Amgen INC. | $33.18 | 2023 | Aimovig |
| Collegium Pharmaceutical, INC. | $30.19 | 2021 | |
| Alexion Pharmaceuticals, INC. | $27.93 | 2024 | Ultomiris |
| Almatica Pharma LLC | $24.82 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $24.06 | 2024 | Onpattro |
| Tanabe Pharma America, INC. | $20.96 | 2024 | |
| Grt US Holding, INC. | $20.19 | 2022 | |
| Merz Pharmaceuticals, LLC | $20.14 | 2025 | Xeomin |
| Merck Sharp & Dohme LLC | $19.17 | 2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Livanova USA, INC. | $16.70 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Neurocrine Biosciences, INC. | $15.70 | 2025 | |
| Arbor Pharmaceuticals, INC. | $14.88 | 2021 | |
| Kyowa Kirin, INC. | $13.94 | 2024 | Nourianz |
| Abbott Laboratories | $12.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Desiree Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.